Maeda S - Search Results

1

Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.

Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Yamagishi S, et al. Among authors: maeda s. Biochim Biophys Acta. 2012 May;1820(5):663-71. doi: 10.1016/j.bbagen.2011.03.014. Epub 2011 Apr 2. Biochim Biophys Acta. 2012. PMID: 21440603 Review.

2

Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products.

Maeda S, Matsui T, Ojima A, Takeuchi M, Yamagishi S. Maeda S, et al. Nutr Res. 2014 Sep;34(9):807-13. doi: 10.1016/j.nutres.2014.08.010. Epub 2014 Aug 29. Nutr Res. 2014. PMID: 25241332

3

Pigment epithelium-derived factor improves metabolic derangements and ameliorates dysregulation of adipocytokines in obese type 2 diabetic rats.

Matsui T, Nishino Y, Ojima A, Maeda S, Tahara N, Yamagishi SI. Matsui T, et al. Among authors: maeda s. Am J Pathol. 2014 Apr;184(4):1094-1103. doi: 10.1016/j.ajpath.2013.12.032. Epub 2014 Feb 13. Am J Pathol. 2014. PMID: 24530621

4

DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice.

Ojima A, Matsui T, Maeda S, Takeuchi M, Inoue H, Higashimoto Y, Yamagishi S. Ojima A, et al. Among authors: maeda s. Lab Invest. 2014 Apr;94(4):422-9. doi: 10.1038/labinvest.2014.5. Epub 2014 Feb 10. Lab Invest. 2014. PMID: 24514068

5

Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.

Maeda S, Yamagishi S, Matsui T, Nakashima S, Ojima A, Maeda S, Nishino Y, Ishibashi Y, Yoshida Y, Yamakawa R. Maeda S, et al. Ophthalmic Res. 2013;50(4):221-6. doi: 10.1159/000354116. Epub 2013 Sep 25. Ophthalmic Res. 2013. PMID: 24081217

6

Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.

Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Ishibashi Y, et al. Among authors: maeda s. Cardiovasc Diabetol. 2013 Aug 28;12:125. doi: 10.1186/1475-2840-12-125. Cardiovasc Diabetol. 2013. PMID: 23984879 Free PMC article.

7

Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A.

Ishibashi Y, Matsui T, Ojima A, Nishino Y, Nakashima S, Maeda S, Yamagishi S. Ishibashi Y, et al. Among authors: maeda s. Microvasc Res. 2012 Nov;84(3):395-8. doi: 10.1016/j.mvr.2012.06.008. Epub 2012 Jun 30. Microvasc Res. 2012. PMID: 22750392

8

Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase-mediated oxidative stress generation.

Maeda S, Matsui T, Takeuchi M, Yamagishi S. Maeda S, et al. Int J Cardiol. 2011 Nov 3;152(3):408-10. doi: 10.1016/j.ijcard.2011.08.043. Epub 2011 Sep 10. Int J Cardiol. 2011. PMID: 21911269 No abstract available.

9

Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.

Maeda S, Matsui T, Takeuchi M, Yamagishi S. Maeda S, et al. Diabetes Metab Res Rev. 2013 Jul;29(5):406-12. doi: 10.1002/dmrr.2407. Diabetes Metab Res Rev. 2013. PMID: 23508966

10

Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.

Maeda S, Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K, Yamagishi S. Maeda S, et al. Pharmacol Res. 2011 Mar;63(3):241-8. doi: 10.1016/j.phrs.2010.11.008. Epub 2010 Nov 27. Pharmacol Res. 2011. PMID: 21115116

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results